Kentucky Retirement Systems Sells 219 Shares of DaVita Inc. (NYSE:DVA)

Kentucky Retirement Systems lessened its holdings in DaVita Inc. (NYSE:DVA) by 5.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,091 shares of the company’s stock after selling 219 shares during the period. Kentucky Retirement Systems’ holdings in DaVita were worth $565,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new stake in DaVita in the 4th quarter valued at $30,000. Principal Securities Inc. bought a new stake in DaVita in the 4th quarter valued at $37,000. GAMMA Investing LLC bought a new stake in DaVita in the 4th quarter valued at $60,000. Quent Capital LLC increased its position in DaVita by 21.0% during the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after buying an additional 101 shares during the period. Finally, Quest Partners LLC bought a new position in DaVita during the 4th quarter worth $74,000. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DVA shares. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Truist Financial increased their price objective on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. TD Cowen increased their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Barclays increased their price objective on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Monday, May 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $146.00.

DaVita Price Performance

Shares of NYSE DVA traded up $2.15 during mid-day trading on Monday, reaching $139.56. The company had a trading volume of 140,673 shares, compared to its average volume of 836,230. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. DaVita Inc. has a one year low of $71.51 and a one year high of $147.93. The firm has a market cap of $12.24 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 1.05 and a beta of 0.87. The business’s 50-day simple moving average is $140.63 and its 200 day simple moving average is $131.52.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter last year, the business earned $1.58 earnings per share. DaVita’s revenue was up 6.9% on a year-over-year basis. On average, research analysts predict that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Insider Activity at DaVita

In related news, Director Barbara J. Desoer sold 5,030 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the sale, the director now directly owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.